Paragazole Shows Promise in Preclinical Study 2017-04-04T19:27:17+00:00

Paragazole Shows Promise in Preclinical Study

Date of presentation: April 7, 2013

The investigational drug paragazole showed promising activity against triple-negative breast cancer cells in a preclinical study (a study conducted in the lab). These results were presented at the 2013 annual meeting of the American Association for Cancer Research.

Paragazole is a type of drug known as a histone deacetylase (HDAC) inhibitor. Previous laboratory studies have suggested that HDAC inhibitors may cause triple-negative breast cancer cells to express estrogen receptors.

To explore the effects of paragazole, researchers tested it on several different types of breast cancer cells. Paragazole was tested alone and in combination with chemotherapy drugs.

Paragazole decreased breast cancer cell growth, with the strongest effect seen in triple-negative breast cancer cells. The combination of paragazole with chemotherapy further decreased cell growth. Paragazole also caused increased estrogen receptor expression within cells.

These results suggest that paragazole may be active against triple-negative breast cancer, and may enhance the effects of chemotherapy. The researchers recommend further study, including study of paragazole in combination with hormonal therapies such as tamoxifen.

< back

Astling DP, Tentler JJ, Cross BR et al. A novel class I histone deacetylase (HDAC) inhibitor, paragazole, demonstrates antiproliferative and proapoptotic effects in triple-negative breast cancer models. Presented at the 2013 annual meeting of the American Association for Cancer Research. Washington, DC, April 6-10, 2013. Abstract 1006.[ Full text available here ]

Bookmark and Share